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Economicsa b s t r a c t
Background: Routine maternal immunisation against influenza and pertussis are recommended by the
WHO to protect mother and child, and new vaccines are under development. Introducing maternal vac-
cines into national programmes requires an understanding of vaccine delivery costs – particularly in low
resource settings.
Methods: We searched Medline, Embase, Econlit, and Global Health for studies reporting costs of deliv-
ering vaccination during pregnancy but excluded studies that did not separate the vaccine purchase price.
Extracted costs were inflated and converted to 2018 US dollars.
Results: Sixteen studies were included, of which two used primary data to estimate vaccine delivery
costs. Costs per dose ranged from $0.55 to $0.64 in low-income countries, from $1.25 to $6.55 for
middle-income countries, and from $5.76 to $39.87 in high-income countries.
Conclusions: More research is needed on the costs of delivering maternal immunisation during preg-
nancy, and of integrating vaccine delivery into existing programmes of antenatal care especially in low
and middle-income countries.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
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In the last decade maternal immunisation has become a rapidly
expanding area of research and clinical practice to protect preg-
nant women and children from vaccine preventable diseases [1].
In particular this has been motivated by the high mortality
amongst neonates and young infants, with newborns accounting
for almost half of all deaths in children under 5 years [2], and end-
ing preventable newborn deaths by 2030 is a priority of the United
Nations Sustainable Development Goals. Part of this disparity in
outcomes is due to the burden of infectious diseases and higher
risk posed by some infections during the first weeks or months
of life before the commencement of routine childhood immunisa-
tion schedules. Vaccination of pregnant women offers a means to
protect newborns by bridging this gap in immunity through the
transfer of maternal antibodies in utero [3].
Maternal immunisation with Tetanus Toxoid (TT) was first
introduced into the World Health Organisation (WHO) Extended
Programme on Immunisation (EPI) in the 1970s and has been a
key tool in subsequent efforts to eliminate the burden of maternal
and neonatal tetanus. During the 2009 influenza H1N1 pandemic it
was recognised that pregnant women experienced a higher risk of
severe complications and death, which led the WHO’s Strategic
Advisory Group of Experts (SAGE) on immunisation to identify
pregnant women as the highest priority group for influenza vacci-
nation [3,4]. Around the same time a randomized trial conducted
in Bangladesh showed that vaccinating pregnant women reduced
the risk of influenza in their newborn infants [5]. In 2012, both
the United States and United Kingdom (UK) adopted routine
administration of Tetanus, Diphtheria and Acellular Pertussis
(Tdap) vaccine during pregnancy to prevent pertussis in young
infants [3]. Subsequently, the routine vaccination of pregnant
women against pertussis and influenza are increasingly being rec-
ommended as part of national immunisation programmes [6].
There is growing interest in the potential for maternal immuni-
sation using other vaccines such as pneumococcal conjugate (PCV),
Haemophilus influenzae type B (HiB) and meningococcal vaccines,
as well as the potential for new vaccines against Cytomegalovirus,
Zika virus and malaria [7,8]. Of particular note are vaccines being
developed against group B streptococcus (GBS) and respiratory
syncytial virus (RSV) [8,9], which could become the first vaccines
specifically designed and licensed for use in pregnancy to protect
the unborn child. As these and other vaccines progress towards
market an understanding of the delivery costs in different settings
will be important for assessing the cost-effectiveness and financial
impact of their introduction. Furthermore, these costs may differ
from vaccine delivery in other populations such as routine child-
hood immunisation, for example there may be costs associated
with setting up new delivery channels outside of existing EPI pro-
grammes and costs of integrating delivery within antenatal care
(ANC) programmes.
The objective of this study was to review the literature on the
financial and economic non-vaccine costs of delivering maternal
immunisation and incorporating it into routine, nation-wide vacci-
nation programmes. The findings from this review can be used to
inform economic evaluations of maternal immunisation, including
current vaccines such as influenza and PCV, and prospective vacci-
nes against RSV and GBS.2. Methods
We performed a systematic search of the global literature to
identify studies that reported the costs of delivering maternal
immunisations during pregnancy. Searches were performed across
Medline, Embase, Econlit, and Global Health bibliographicdatabases. The search strategy incorporated a mixture of index
terms and key words which combined the concepts of: (i) vaccina-
tion; (ii) pregnancy; (iii) costs, and (iv) diseases with existing or
pipeline vaccines recommended for maternal immunisation. The
list of included vaccines was based on a recent review by Omer
[3], and the full search strategy and complete list of search terms
are provided in the supplementary material.
We included any English language articles that reported esti-
mates of the non-vaccine cost of vaccinating pregnant women
and excluded studies that reported only a vaccine purchase price,
or for which the vaccine delivery and purchase costs could not
be separated. We excluded articles where cost estimates were
not specific to our population of interest, including estimates for
vaccinating women of childbearing age that did not distinguish
women who were pregnant. Studies were included regardless of
the data source for cost estimation including estimates based on
primary and secondary data, government tariffs, expert opinion,
and assumption.
Search results were combined using reference management
software (Mendeley) and any duplicate records were removed.
Two reviewers (OS and SP) screened articles using titles and
abstracts, followed by full text screening of potentially eligible
studies to determine the final list of included articles. We recorded
descriptive study characteristics including the country, currency
and year of cost estimates, type of vaccine, and details of source
data and methodology for cost estimation. We extracted reported
non-vaccine delivery costs related to immunisation of pregnant
women – this included total programme costs, cost per dose,
and any component costs which were separately reported. In addi-
tion we also recorded the reported price of purchasing a vaccine
dose.
Extracted costs were inflated to 2018 currency values using
national GDP deflators [10] from the World Bank, and figures
reported in local currency units were then converted into United
States Dollars (USD) using the average 2018 exchange rates [11].
Results were also converted to international dollars (I$) using Pur-
chasing Price Parity (PPP) conversion rates [12]. Where possible we
calculated cost per dose if this was not already reported by the
study authors.3. Results
Our initial search resulted in 1523 records across the different
databases, and 1053 unique articles once duplicates were removed.
Following the first stage of screening we identified 98 potentially
eligible articles, and after full-text screening there were 16 articles
that met the inclusion criteria. The flow diagram summarising the
results of our search and screening is shown in Fig. 1.
Key characteristics of the articles included are summarised in
Table 1, and further details are provided in the supplementary
material. Eleven studies were from high-income countries (HICs)
[13–23], with three studies in middle-income countries
(MICs) [13,24,25] and only two studies in low-income countries
(LICs) [26,27]. The studies covered four existing vaccines – Tetanus
Toxoid, Tdap, Influenza, and Hepatitis E – as well as the hypothet-
ical introduction of a new vaccine against GBS. Six studies reported
costs for delivering vaccines as part of routine ANC visits, while the
remaining studies did not make this explicit. Although we applied
no date limits to our search, all but one of the articles were pub-
lished since 2010 reflecting the recent and growing interest in
the introduction of maternal vaccines to national programmes.
Globally the estimated cost per dose of delivering maternal
immunisation in 2018 USD ranged from $0.55 in Malawi [26] to
$39.87 in Canada [28]. Reported costs ranged from $0.55 to $0.64
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Fig. 1. Flow diagram showing the screening process used to identify included studies.
Table 1
Descriptive characteristics of included studies.
Lead author Year Country Vaccine Study
type









Atkins 2016 USA Tdap EE Literature Not specified
Baguelin 2010 UK Influenza EE Government tariff Not specified
Berman 1991 Indonesia TT EE Primary data X X Yes
Fernández-Cano 2015 Spain Tdap EE Government tariff Not specified
Garcia 2016 Spain Influenza EE Government tariff Not specified
Giorgakoudi 2018 UK GBS EE Government tariff Not specified
Jit 2010 UK Influenza EE Government tariff + secondary data Not specified
Kim 2014 South Africa GBS EE Secondary data + expert opinion X Yes
Kim 2017 USA GBS EE Secondary data + expert opinion X Yes
Pecenka 2017 Malawi Influenza Cost study Primary + secondary data X X Yes
Sartori 2016 Brazil Tdap EE Secondary data X Yes
Skedgel 2011 Canada Influenza EE Government tariff / unpublished estimatea Not specified
Terranella 2013 USA Tdap EE Assumption Not specified
van Hoek 2016 UK Tdap EE Assumption Not specified
Xu 2016 USA Influenza EE Literature Yes
Zhao 2016 China Hepatitis E EE Literature Not specified
EE = Economic Evaluation; TT = Tetanus Toxoid; Tdap = Tetanus, diphtheria & acellular pertussis
a Private communication from Nova Scotia Department of Health Promotion and Protection.
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in the purchasing power of each dollar, we also present results in
Table 2 using I$ to facilitate comparisons between countries. All
of the studies reported costs from the health care (payer / provider)perspective; however, this perspective included different costs in
different studies.
Only two studies undertook detailed costing of maternal vac-
cine programmes through the collection of primary data on
Table 2
Reported cost per dose for delivery of maternal vaccination.
Study Author Year Country Delivery cost per dose (range) Vaccine price
2018 USD 2018 I$ 2018 USD
Low-income
Pecenka 2017 Malawi 0.55 (0.55 – 0.83) 1.81 (1.81 – 2.73) 3.06
Bermana 1991 Indonesia 0.64 (0.44 – 2.80) 2.14 (1.48 – 9.40) 0.28
Upper-middle income
Zhao 2016 China 1.25 2.33 19.77
Sartori 2016 Brazil 2.14 3.86 13.96
Kimb 2014 South Africa 6.55 (3.28 – 9.83) 14.06 (7.04 – 21.10) 23.01
High-income
Skedgelc 2011 Canada 5.76 5.99 3.23
Baguelin 2010 UK 8.30 8.89 16.92
van Hoek 2016 UK 10.39 11.12 18.54
Fernández-Cano 2015 Spain 10.46 13.68 12.16
Jit 2010 UK 11.87 (8.69 – 16.33) 12.71 (9.31 – 17.48) 10.22
Garciad 2016 Spain 12.85 16.81 14.51
Giorgakoudi 2018 UK 13.87 14.84 81.79
Xu 2016 USA 17.15 (8.79 – 17.15) 17.15 (8.79 – 17.15) 13.41
Terranella 2013 USA 22.54 (11.27 – 33.81) 22.54 (11.27 – 33.81) 42.37
Atkins 2016 USA 24.20 24.20 23.15
Kime 2017 USA 25.96 (12.13 – 40.22) 25.96 (12.13 – 40.22) 116.41
Skedgelf 2011 Canada 39.87 41.51 3.23
a We extracted the delivery cost per pregnant woman receiving two doses of TT from figure 3 of Berman et al. for each sub-district and converted to cost per dose by
dividing by 2; to calculate the average cost across all sub-districts we used total number of TT doses per district reported in Table 1 of Berman et al. (in total 2293 women
received two doses).
b Vaccine price based on mid-point of assumed public sector price range
c Delivery cost based on unpublished estimate of average cost of vaccine delivery in a public health clinic.
d Vaccine price for quadrivalent influenza vaccine.
e Vaccine price based on assumed public sector price.
f Delivery cost based on government fee schedule for delivery by family physician.
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financial cost to the government of $0.64 per dose for an on-
going tetanus maternal immunisation programme provided as part
of routine antenatal care (ANC) in Aceh province, Indonesia [27].
More recently, Pecenka et al. estimated the financial cost to be
$0.55 per dose for incorporating a prospective programme of sea-
sonal influenza immunisation alongside existing antenatal care
provision in Malawi [26].
The majority of the articles described economic evaluations
where detailed estimation of vaccination delivery costs was not a
primary research objective and differed in their approaches to cost
estimation. In addition to the studies by Berman and Pecenka, only
three other studies by Kim [13,23] and Sartori [25] used an
ingredients-based approach in which some disaggregation of
resource use was used to estimate an overall vaccine delivery cost
(a summary of individually reported cost components is provided
in the supplementary material) [13,23,25–27]. Six studies in the
UK, Spain and Canada estimated costs using government tariffs
or fees for a physician visit [14,16–19,28]. The remaining five arti-
cles either reported costs based on the authors’ assumption or
cited estimates of vaccine administration costs from the literature,
however the sources of these estimates were not specific to vacci-
nating pregnant women [15,20–22,24].4. Discussion
Methodological differences between studies may have lead to
important differences in estimated costs. For example, where esti-
mates were based on tariffs or fees these service payments might
reflect the marginal cost from the perspective of the healthcare
payer. However, they may not necessarily represent the true eco-
nomic cost of vaccine delivery, which will depend on the actual
resources used in the providing the service. As an illustration, Jit
et al. estimated the cost of delivering maternal influenza vaccinein the UK to be $11.87 per dose based on a National Health Service
(NHS) tariff payment [17]. In contrast estimates based on the
appointment duration and valuation of nurses’ time ranged from
$8.69 to $16.33 per dose depending on the grade of nurse deliver-
ing the vaccine.
A further consideration is that estimates based only on tariffs
and fees are likely to neglect any costs of introducing a new vac-
cine programme that are borne centrally by the government or
health service. Two of the studies that used an ingredients-based
approach reported costs of programme introduction including
expenditure on planning, training, social mobilisation and capital
investment in cold chain capacity [13,26]. In the South African
study by Kim et al. these costs accounted for $1.44 (22%) of the
delivery costs per dose based on estimates using previously pub-
lished analysis from other vaccine programmes. Figures reported
by Pecenka et al. showed that introduction costs were $0.36
(66%) of the total non-vaccine costs per dose, and that the start-
up costs were ~ 3 times higher in the first year of the programme.
These findings highlight the importance of these costs and of con-
sidering whether or not they have been included when drawing
comparisons across studies.
The relative contribution of fixed costs – which do not change in
the short-run – and variable costs that increase with the number of
vaccinations can be an important determinant of programme effi-
ciency and the overall cost per dose. For example, in their base case
analysis, Pecenka et al. found the financial cost per dose was $0.55,
but due to the effect of fixed programme costs this increased to
$0.83 per dose in a sensitivity analysis which assumed lower vac-
cine coverage. Similarly, Berman et al. reported an average vaccine
delivery cost of $0.64 per dose, but this ranged across sub-districts
from $0.44 to $2.80 per dose. The authors found that this variation
was primarily driven by the amortisation of fixed programme costs
across substantially different numbers of women vaccinated in
each sub-district. These fixed costs did not depend on how many
women were vaccinated and included both capital investment in
S.R Procter et al. / Vaccine 38 (2020) 6199–6204 6203equipment as well as recurrent expenditure on wages and allow-
ances for certain personnel.
For the five studies in our sample conducted in LMICs our find-
ings for maternal immunization are broadly similar to the results
of a recent review on the costs of immunisation delivery in LMICs
more generally, which reported costs per dose ranging from $0.16
to $2.54 (in 2016USD) [29]. Only Kim’s estimate for South Africa fell
outside this range [13]. However, given the small number of studies
we identified it is difficult to draw general conclusions about the
extent to which estimates from other types of vaccine programme
can inform the cost of maternal immunisation. More primary data
are needed to establish how these costs vary across different
income settings, and across different health systems with different
levels of existing antenatal care provision. There is also a need for
more evidence on whether general tariffs and fees are a reasonable
proxy of vaccine delivery costs amongst pregnant women. Good
cost estimates are important for informing decisions on the cost-
effectiveness of adopting existing and new maternal vaccines.
For decision makers the relative importance of non-vaccine
delivery costs may be influenced by the vaccine purchase price.
Amongst our included studies we found non-vaccine costs as a pro-
portion of the total cost ranged from 15% to 70% in LICs, 6% to 22%
in MICs, and 14% to 93% in HICs. The broad ranges largely reflect
the variation in vaccine purchase price (Table 1), which in general
are higher for newer vaccines. Although high purchase prices for
new vaccines may be cost-prohibitive in lower-income settings,
the non-vaccine delivery costs could still be an important determi-
nant in influencing expansion of maternal immunisation where
purchase costs are funded or subsidised through external donor
support, or for vaccines that are relatively cheap such as Tdap or
TT vaccines.
Of the studies we found only one used a dedicated costing tool
[30], although several tools exist to support costing of immunisa-
tion programmes such as the WHO FLUtool, the comprehensive
Multi-Year Planning (cMYP) costing tool, and the ONE Health tool
[30–32]. To improve the comparability of cost estimates future
research should follow immunisation costing guidelines and more
standardisation is needed in terms of methodological approach and
transparency in the reporting of findings.
Another limitation in the literature was the lack of studies
examining costs from the perspective of pregnant women and their
families. The costs of transport and time spent attending appoint-
ments may act as a barrier to the uptake of maternal immunisa-
tion, but these additional costs may be avoided where maternal
vaccines can be delivered as part of existing ANC visits. In this case
the health benefits of introducing new maternal vaccines could
even act as an incentive helping to boost coverage of wider antena-
tal care packages.
Our study is subject to several limitations. First, we have not
formally appraised the quality of the included studies for factors
which may bias the reported cost estimates. However, we do
report study methodology - there is a generally accepted hierarchy
in which estimates using ingredients-based costing are usually
considered better than those based on tariffs [33], and the quality
of estimates based purely on assumption cannot be judged. Second,
we included only studies that were written in English and excluded
articles in other languages. Finally, we searched only the peer-
reviewed academic literature, and therefore do not include infor-
mation that may exist in the grey literature.5. Conclusion
We found few studies in the academic literature that reported
estimates of the costs of delivering maternal immunisation to
pregnant women, and only two studies that collected primary dataon resource use. This highlights the need for further research to
identify the economic and financial costs of delivering vaccinations
during pregnancy. More detailed costing studies are needed that
use primary data and micro-costing to establish whether the
non-vaccine costs of maternal immunisation delivery differ from
other immunisations programmes, and the extent to which such
differences may vary by setting. Studies should consider the
start-up costs of introducing new maternal immunisation pro-
grammes, and the costs of integrating delivery within existing
antenatal care services. A good understanding of these costs is crit-
ical to informing the cost-effectiveness and financial impact of
introducing new maternal vaccines, particularly in low-resource
settings.
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